Nodal recurrence
|
Age
|
Stage
|
Grade
|
LVSI
|
HIR
|
Nodal assessment
|
Adjuvant therapy
|
Nodal recurrence
|
Concurrent recurrence sites
|
---|
I
|
57
|
1B
|
2
|
Present
|
Y
|
Pelvic
|
Vaginal brachytherapy
|
Pelvic
|
–
|
II
|
61
|
1A
|
2
|
Absent
|
N
|
Pelvic
|
Megestrol acetate
|
Pelvic
|
Lungs
|
III
|
54
|
1A
|
1
|
Absent
|
N
|
Pelvic
|
None
|
Pelvic
|
Vaginal vault
|
IV
|
72
|
1B
|
3
|
Present
|
Y
|
Pelvic and PA
|
Pelvic EBRT
|
Pelvic, para-aortic
|
–
|
V
|
65
|
1A
|
3
|
Present
|
Y
|
Pelvic and PA
|
None
|
Pelvic
|
Vaginal vault, bone
|
VI
|
52
|
1B
|
2
|
Present
|
Y
|
Pelvic
|
None
|
Pelvic
|
–
|
VII
|
64
|
1B
|
2
|
Present
|
Y
|
Pelvic
|
None
|
Pelvic
|
Vaginal vault
|
VIII
|
77
|
1B
|
3
|
Present
|
Y
|
Pelvic and PA
|
Vaginal brachytherapy
|
Pelvic
|
Abdomen
|
IX
|
67
|
1B
|
3
|
Present
|
Y
|
Pelvic
|
Pelvic EBRT
|
Mediastinum
|
–
|
X
|
70
|
1A
|
3
|
Present
|
Y
|
Pelvic
|
Pelvic EBRT
|
Mediastinum
|
Brain
|
XI
|
65
|
1A
|
3
|
Present
|
Y
|
Pelvic and PA
|
Chemotherapy
|
Para-aortic
|
Abdomen
|
- LVSI lymphovascular space invasion, HIR high-intermediate risk, Y yes, N no, EBRT external beam radiation therapy, PA para-aortic